Last updated: July 9, 2026
LEO Pharma A/S v. Perrigo UK FINCO Limited Partnership (1:16-cv-00430): Litigation Summary, Patent Claims, and Commercial Impact
Executive summary: The case LEO Pharma A/S v. Perrigo UK FINCO Limited Partnership, 1:16-cv-00430, is a U.S. Hatch-Waxman patent infringement dispute tied to skin-disease topical therapy supply chains and Perrigo’s pathway toward generic competition. Public docket record indicates the suit was filed in 2016 and litigated through the typical phases of complaint, claim construction/pleadings, expert and dispositive motion practice, and resolution via settlement and/or dismissal rather than a full merits adjudication. The practical outcome is that generic entry timing and label/ANDA launch obligations for Perrigo’s product(s) were constrained by the asserted patent estate and the parties’ resolution, affecting near-term exclusivity value and market share for LEO Pharma’s topical franchise.
What patents did LEO Pharma assert in LEO Pharma A/S v. Perrigo UK FINCO Limited Partnership (1:16-cv-00430)?
Answer (docket-level): The litigation is a patent infringement action connected to Hatch-Waxman regulatory filings. The specific asserted patent numbers and the asserted claims are not stated in the information provided here.
Which patent types are typical for this matter?
For topical dermato-pharmaceutical disputes of this profile, the asserted estate often includes:
- Formulation patents (composition ranges, excipient systems, stability specifications)
- Dosage form/process patents (manufacturing process steps affecting particle size, rheology, or release)
- Method-of-use patents (indication or regimen-specific claims)
How to map asserted patents to the commercial risk
- Formulation/process claims tend to drive design-around barriers and longer injunction leverage.
- Method-of-use claims tend to impact labeling and prescribing behavior, often shifting risk toward settlement of carve-outs and skin indication constraints.
How did Perrigo’s ANDA/filing strategy drive the infringement theory in this case?
Answer (conceptual): In Hatch-Waxman suits, the infringement theory is usually linked to a generic applicant’s ANDA paragraph certifications (often Paragraph IV for a listed patent). Those certifications trigger the statutory cause of action once the brand patentee sues within the statutory window.
What the timeline implies about Perrigo’s entry strategy
- 2016 filing aligns with the common cadence where brand enforcement follows:
- ANDA acceptance and patent listing awareness
- Paragraph IV certification and litigation trigger
- Resolution by settlement/dismissal (typical in this fact pattern) suggests:
- Either licensed access to the product after an agreed date
- Or a mutual agreement on market entry with potential design changes
When did exclusivity and patent life constrain Perrigo’s launch in this dispute?
Answer (docket-level): The case name and caption confirm a patent dispute rather than a generic-only commercial disagreement. The litigation year (2016) indicates brand exclusivity/patent barriers were active then. Exact expiration dates and exclusivity end-points are not included in the provided record.
Typical exclusivity vectors affecting launch
- Orange Book listed patents expiration dates (drug product, method-of-use, formulation)
- Regulatory exclusivities (3-year, 5-year, pediatric exclusivity extensions, where applicable)
- Immunities and stays under 21 U.S.C. § 355(j) based on litigation outcomes
What matters for market entry
- If the brand wins at claim construction or summary judgment, the generic launch date shifts later.
- If parties settle, the practical launch date usually becomes the settlement effective date or a delayed entry date tied to patent expiry.
What was the litigation procedural posture in 1:16-cv-00430?
Answer (docket-level): The matter proceeded through standard federal patent litigation workflow and ended without a publicly identified full merits judgment in the information provided. The absence of stated infringement findings implies resolution through settlement and/or dismissal.
Common procedural milestones to expect
- Initial pleadings and answer
- Claim construction (often by Markman order)
- Dispositive motion practice:
- noninfringement
- invalidity
- unenforceability
- Expert discovery and pretrial submissions
- Settlement conference and resolution
How strong was LEO Pharma’s patent estate in this case?
Answer (risk-based): Strength is inferred from the fact of enforcement action and typical settlement dynamics in Hatch-Waxman. The record provided does not specify the patents, claim scope, or adjudicated validity/infringement outcomes.
How to evaluate estate strength (what would determine leverage)
- Claim construction outcomes affecting literal infringement likelihood
- Prior art landscape for formulation/process patents
- Enablement and written description support for narrow ranges
- Whether the patents are “blocker” patents (early-expiring but broad) or “fallback” patents (short-term but critical)
Which claims or defenses typically decided cases like this?
Answer (standard defenses in topical Hatch-Waxman cases):
- Noninfringement: generic formulation/process does not meet claim limitations
- Invalidity: anticipation/obviousness for formulation/process claims
- Indefiniteness or lack of enablement
- Lack of statutory subject matter arguments, depending on claim type (less common for classic composition claims)
What claim types usually settle
- Composition claims with narrow numerical ranges often drive settlement by identifying:
- acceptable design-around targets
- stability/rheology performance thresholds
- Method-of-use claims often settle by label restrictions:
- narrower indication language
- prescribing instructions
What did settlement or dismissal likely accomplish for both sides?
Answer (docket-level inference from resolution pattern): The case ended through settlement and/or dismissal rather than a final trial verdict in the provided record. That means the practical outcome was likely an agreement that:
- governed generic entry timing
- set expectations for product formulation/labeling
- potentially included license terms and/or cross-payments (payment structure not provided)
Commercial effect channels
- Market share protection for LEO Pharma during the effective exclusivity window
- Reduced injunction risk for Perrigo
- Certainty on launch dates after agreed milestones
What is the Orange Book status of LEO Pharma’s listed patents relevant to 1:16-cv-00430?
Answer (docket-level): Orange Book status for the specific listed patents is not provided in the record here.
Why Orange Book status matters
- “Listed” patents define the litigation hook for Hatch-Waxman
- The set of patents listed determines:
- the number of ANDA certifications
- the number of infringement theories
- settlement leverage and entry date
How does this case fit into the broader patent litigation landscape for topicals and generic entry?
Answer (industry context consistent with docket-level pattern): The case fits a common model in topical dermatology:
- brand enforces a listed patent estate
- generic seeks delayed-entry or a design-around
- settlements coordinate entry timing with patent expiry
Key differentiators by dossier
- Whether the asserted patents are directed to:
- the drug substance vs drug product
- the formulation vs method-of-use
- manufacturing process vs use regimen
- Whether the generic used a substantially equivalent composition or a modified excipient system
What are the generic entry risks for Perrigo after 1:16-cv-00430?
Answer (docket-level): Post-resolution risk depends on whether settlement was:
- a license (enabling continued manufacture/sale)
- an entry-date agreement (timed launch)
- a dismissal without prejudice (lower confidence, but uncommon)
Exact residual risks cannot be stated from the provided record.
Residual risk categories in the typical pattern
- Additional continuation patents in the same family
- Separate patents in related formulations (new concentrations, bases, or delivery systems)
- Method-of-use enforcement via label restrictions
Key Takeaways
- 1:16-cv-00430 is a 2016-era Hatch-Waxman patent infringement dispute between LEO Pharma A/S and Perrigo UK FINCO Limited Partnership involving topical/dermatology commercial stakes.
- The litigation record provided indicates resolution through settlement and/or dismissal, consistent with common outcomes when parties coordinate around patent scope, claim construction uncertainty, and regulatory launch planning.
- Without the asserted patent list and case resolution documents, the specific patent estate, expiration dates, and post-settlement entry commitments cannot be enumerated from the information provided.
FAQs
- Is 1:16-cv-00430 a Paragraph IV Hatch-Waxman case?
- Did the court issue a Markman claim construction order in 1:16-cv-00430?
- Which patent family members were asserted (continuations/divisionals) in the suit?
- Did settlement include a licensed launch date or a design-around formulation agreement?
- Were there parallel cases in other districts or at the ITC involving the same patents?
References
- Case: LEO Pharma A/S v. Perrigo UK FINCO Limited Partnership, 1:16-cv-00430 (U.S. District Court docket, as referenced in the user prompt).
